

Attorney Docket No.: 10065.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Outrup et al. O P E Confirmation No: 3473

Serial No.: 09/913,701 Group Art Unit: 1633

Filed: August 16, 2001 Examiner: To be assigned

For: Subtilase Enzymes



INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. US 6,017,871
2. WO 99/27082
3. WO 98/20115
4. US 5,500,364
5. WO 01/44452

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

RECEIVED
PATENT & TRADEMARK OFFICE
TECH CENTER 1600/2900
MAY 03 2002

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: June 25, 2002


Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Attorney Docket No.: 10065.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Outrup et al.

Serial No.: 09/913,701

Filed: August 16, 2001

For: Subtilase Enzymes



Confirmation No: 3473

Group Art Unit: 1633

Examiner: To be assigned

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box DD
Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box DD
Commissioner for Patents
Washington, DC 20231

on June 25, 2002.

Julie Tabarovsky
(name of person mailing paper)

J. Tabarovsky
(signature of person mailing paper)

RECEIVED
#3
JUL 3 2002
PATENT
TECH CENTER 1600/2900
1633



EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.